Cell and Gene Therapy Third-Party Logistics Market

Cell and Gene Therapy Third-Party Logistics Market Analysis and Forecast by Fact.MR

• The global cell and gene therapy third-party logistics market covers specialized logistics services for the storage, handling, and transportation of living cell products and gene therapy vectors under controlled temperature and chain-of-custody conditions.
• Service categories include clinical trial logistics, commercial distribution, cryogenic storage, last-mile delivery, and regulatory documentation management.
• These services support biopharmaceutical companies, hospitals, and transplant centers.
• Growth is shaped by the rapidly expanding CGT product pipeline, increasing commercial launches, and the complex logistics requirements of personalized autologous therapies.

Summary of Cell and Gene Therapy Third-Party Logistics Market

• Market Snapshot
  • In 2025, the global Cell and Gene Therapy Third-Party Logistics Market was valued at approximately USD 11.9 billion.
  • The market is estimated to reach USD 13.26 billion in 2026 and is projected to attain USD 39.02 billion by 2036.
  • The cell and gene therapy third-party logistics market is likely to expand at a CAGR of 11.4% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 25.76 billion between 2026 and 2036.
  • Cell Therapies accounts for 66% of product share in 2026.
  • India (13.5%) and China (12.8%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Rapidly expanding CGT product pipeline with over 2,000 active clinical trials globally is creating substantial demand for specialized logistics services.
  • Increasing commercial launches of approved CGT products are shifting logistics requirements from clinical trial support toward high-volume commercial distribution.
  • Complex chain-of-custody and temperature requirements for autologous cell therapies necessitate specialized 3PL providers with cryogenic handling capabilities.
  • Growing geographic reach of clinical trials across emerging markets is requiring global logistics networks with cold chain infrastructure in new regions.
  • Regulatory requirements for complete traceability from manufacturing to patient administration are driving demand for digitally integrated logistics platforms.
• Product and Segment View
  • Cell Therapies accounts for 66% of the product segment in 2026, supported by broad applicability across primary end-use categories.
  • Oncology represents 51% of the therapeutic area segment in 2026, reflecting sustained institutional demand.
  • Key segmentation includes: Type: Clinical, Commercial. Product: Cell Therapies, Gene Therapies. Temperature Range: Ambient Storage, Refrigerated Storage, Ultra Low Temperature Storage, Cryogenic Storage. Therapeutic Area: Oncology, Neurology, Cardiovascular Diseases, Ophthalmology, Infectious Diseases. End Use: Biopharmaceutical Companies, CDMOs CMOs, Others.
• Geography and Competitive Outlook
  • North America maintains a leading position supported by established healthcare infrastructure and strong institutional procurement.
  • Europe shows steady demand driven by regulatory frameworks, clinical standards, and aging demographics.
  • Asia Pacific is the fastest-growing region, led by India (13.5%) and China (12.8%).
  • Key players include Cencora Corporation, Cardinal Health, McKesson Corporation, EVERSANA, Knipper Health, DHL (DE).
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The CGT logistics market is at an inflection point. Clinical trial logistics built the industry, but commercial distribution is now the growth driver. The complexity of autologous therapies, where a single patient's cells must be shipped to a manufacturing site and returned as a finished product, creates logistics requirements that standard pharma 3PLs cannot meet. The commercial opportunity is in end-to-end digital platforms that provide real-time visibility from apheresis to patient infusion, with automated regulatory documentation at every handoff.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising disease prevalence and aging populations are expanding the addressable patient population requiring specialized products.
• Increasing institutional adoption and clinical guideline integration are supporting procurement growth in hospital and long-term care settings.
• Expanding healthcare infrastructure in developing economies is creating new procurement demand across emerging market facilities.

Key Market Constraints

• Cost sensitivity in price-constrained healthcare settings limits adoption of premium products.
• Limited clinical awareness in certain markets restricts demand growth for specialized products.
• Regulatory differences across countries create compliance complexity for manufacturers.

Key Opportunity Areas

• Development of integrated care kits combining multiple product categories creates higher-value procurement opportunities.
• Expansion of homecare programs opens new demand channels beyond traditional institutional settings.
• Product innovation in safety, monitoring, and ease-of-use features supports premiumization.

Segment-wise Analysis of the Cell and Gene Therapy Third-Party Logistics Market

• Cell Therapies holds 66% of the product segment in 2026.
• Oncology represents 51% of the therapeutic area segment in 2026.

The cell and gene therapy third-party logistics market is segmented by type, product, temperature range, therapeutic area, end use, and region.

Which Product Segment Dominates the Cell and Gene Therapy Third-Party Logistics Market?

Cell Therapies is expected to account for approximately 66% of the product segment in 2026. This leadership reflects sustained demand from primary use cases, established procurement patterns, and broad applicability across key end-use categories.

Other segments within this category serve specialized requirements and contribute to overall market diversification. Competition across segments is shaped by product performance, pricing, and alignment with institutional procurement standards.

Which Therapeutic Area Segment Dominates the Cell and Gene Therapy Third-Party Logistics Market?

Oncology is expected to account for approximately 51% of the therapeutic area segment in 2026. Demand is shaped by institutional procurement requirements, clinical adoption patterns, and established end-use applications.

Remaining segments serve specific clinical, demographic, or application needs, each contributing to the overall market through differentiated demand drivers and procurement channels.

Which Product Trend is Shaping the Next Phase of Growth in the Cell and Gene Therapy Third-Party Logistics Market?

Digitally integrated chain-of-identity platforms are emerging as the defining technology trend in CGT logistics. Their adoption is projected to rise as therapy manufacturers shift from manual documentation toward automated digital systems that track patient-specific products from collection through manufacturing and delivery. This is particularly relevant for autologous therapies where chain-of-identity errors can result in wrong-patient administration.

The shift toward digital platforms reflects a broader change in regulatory expectations for CGT logistics. Health authorities are moving from paper-based traceability toward electronic audit trails with real-time visibility. As a result, 3PL providers investing in integrated digital platforms with temperature monitoring, GPS tracking, and automated regulatory documentation are capturing the highest-value logistics contracts from commercial CGT manufacturers.

Regional Outlook Across Key Markets

• India leads growth at 13.5%, supported by expanding healthcare infrastructure and rising demand for specialized products.
• China follows at 12.8%, driven by government healthcare programs and increasing clinical adoption.
• Mature markets show steady growth supported by established healthcare systems and replacement demand.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Cell and Gene Therapy Third-Party Logistics in India

The India cell and gene therapy third-party logistics market is projected to grow at a CAGR of 13.5% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Demand Trends in Cell and Gene Therapy Third-Party Logistics in China

The China cell and gene therapy third-party logistics market is projected to grow at a CAGR of 12.8% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Growth Assessment for Cell and Gene Therapy Third-Party Logistics in Japan

The Japan cell and gene therapy third-party logistics market is projected to grow at a CAGR of 11.9% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Market Analysis of Cell and Gene Therapy Third-Party Logistics in USA

The USA cell and gene therapy third-party logistics market is projected to grow at a CAGR of 10.8% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Opportunity Outlook for Cell and Gene Therapy Third-Party Logistics in Brazil

The Brazil cell and gene therapy third-party logistics market is projected to grow at a CAGR of 10.5% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Competitive Benchmarking and Company Positioning

Cell and Gene Therapy Third-Party Logistics Market Analysis By Company

• Cencora Corporation, Cardinal Health, McKesson Corporation hold strong positions through broad portfolios and established distribution networks.
• EVERSANA, Knipper Health, DHL (DE) compete across specific segments, price tiers, and regional markets.
• Competition is shaped by product quality, clinical evidence, pricing, and distribution capabilities.

The competitive landscape is moderately fragmented, with established medical companies competing alongside specialized manufacturers. Product quality, clinical evidence, and service support drive purchasing decisions.

Strategic priorities include expanding product portfolios, strengthening distribution networks, and developing service-linked revenue models.

Key Companies in the Cell and Gene Therapy Third-Party Logistics Market

Cencora Corporation, Cardinal Health, McKesson Corporation, EVERSANA are among the leading players. Knipper Health, DHL (DE), Kuehne + Nagel, Arvato SE hold established positions. FedEx, United Parcel Service (UPS) compete through focused product offerings.

Recent Industry Developments

• Cencora Corporation - Product Portfolio Expansion (January 2026)
  • Cencora Corporation expanded its product portfolio targeting growing demand segments.
• Cardinal Health - Market Expansion (2025)
  • Cardinal Health broadened geographic presence through distribution partnerships.
• McKesson Corporation - Technology Enhancement (2025)
  • McKesson Corporation introduced technology improvements targeting performance and compliance.

Leading Companies Shaping the Cell and Gene Therapy Third-Party Logistics Market

• Cencora Corporation
• Cardinal Health
• McKesson Corporation
• EVERSANA
• Knipper Health
• DHL (DE)
• Kuehne + Nagel
• Arvato SE
• FedEx
• United Parcel Service (UPS)

Sources and Research References

• Cencora Corporation. Product portfolio and corporate updates.
• Cardinal Health. Product launches and market announcements.
• World Health Organization. Disease prevalence and healthcare infrastructure data.
• Primary interviews with manufacturers, distributors, clinicians, and end users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Cell and Gene Therapy Third-Party Logistics Market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product is likely to lead the market by 2026?
• Which therapeutic area segment accounts for the highest demand?
• What factors are driving demand globally?
• Which countries show the fastest growth through 2036?
• Who are the key companies in the Cell and Gene Therapy Third-Party Logistics Market?
• How does Fact.MR estimate and validate the forecast?
• What are the key constraints and opportunities?
• How is product innovation influencing growth?

Cell and Gene Therapy Third-Party Logistics Market Definition

The CGT 3PL market covers specialized logistics services for storage, handling, and transportation of cell therapy products and gene therapy vectors under controlled temperature and chain-of-custody conditions.

Cell and Gene Therapy Third-Party Logistics Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across key segmentation categories and regions.
• It includes regional demand analysis based on disease prevalence, healthcare spending, institutional procurement patterns, and regulatory frameworks.
• The report covers pricing analysis, competitive landscape, and distribution strategies of leading companies.
• It includes technology trends, product innovation, and emerging market dynamics influencing demand growth.

Cell and Gene Therapy Third-Party Logistics Market Exclusions

• The scope excludes products and services outside the defined market boundary serving different clinical or commercial purposes.
• It excludes non-commercial, custom-built, or research-only systems not available through standard procurement.
• The report excludes informal products with limited quality standardization and market visibility.
• It also excludes adjacent categories that differ in product classification and regulatory pathway.

Cell and Gene Therapy Third-Party Logistics Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25+ interviews across manufacturers, distributors, and end users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.